Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Apr;105(4):787–791. doi: 10.1111/j.1476-5381.1992.tb09058.x

Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist

Yoshitaka Yamamura, Hidenori Ogawa, Hiroshi Yamashita, Tomihiko Chihara, Hisashi Miyamoto, Shigeki Nakamura, Toshiyuki Onogawa, Tatsuya Yamashita, Tetsumi Hosokawa, Toyoki Mori, Michiaki Tominaga, Youichi Yabuuchi
PMCID: PMC1908728  PMID: 1387020

Abstract

1 OPC-31260, a benzazepine derivative, has been studied for its ability to antagonize the binding of arginine vasopressin (AVP) to receptors in rat liver (V1) and kidney (V2) plasma membranes, for antagonism of the antidiuretic action of AVP in alcohol-anaesthetized rats and for diuretic action in conscious normal rats.

2 OPC-31260 caused a competitive displacement of [3H]-AVP binding to both V1 and V2 receptors with IC50 values of 1.2 ± 0.2 × 10-6 M and 1.4 ± 0.2 × 10-8 M, respectively.

3 OPC-31260 at doses of 10 to 100 μg kg-1, i.v., inhibited the antidiuretic action of exogenously administered AVP in water-loaded, alcohol-anaesthetized rats in a dose-dependent manner. OPC-31260 did not exert an antidiuretic activity suggesting that it is not a partial V2 receptor agonist.

4 After oral administration at doses of 1 to 30 mg kg-1 in normal conscious rats, OPC-31260 dose-dependently increased urine flow and decreased urine osmolality. The diuretic action of OPC-31260 was characterized as aquaresis, the mode of diuretic action being different from previously known diuretic agents such as furosemide, hydrochlorothiazide and spironolactone.

5 The results indicate that OPC-31260 is a selective V2 receptor antagonist and behaves as an aquaretic agent. OPC-31260 will be a useful tool in studying the physiological role of AVP and in the treatment of various conditions characterized by water retention.

Keywords: OPC-31260, vasopressin, nonpeptide antagonist, aquaresis, V2 receptor

Full text

PDF
787

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albrightson-Winslow C. R., Caldwell N., Brooks D. P., Huffman W. F., Stassen F. L., Kinter L. B. Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs. J Pharmacol Exp Ther. 1989 May;249(2):366–371. [PubMed] [Google Scholar]
  2. BISSET G. W., LEWIS G. P. A spectrum of pharmacological activity in some biologically active peptides. Br J Pharmacol Chemother. 1962 Aug;19:168–182. [PMC free article] [PubMed] [Google Scholar]
  3. Bisset G. W., Chowdrey H. S. A cholinergic link in the reflex release of vasopressin by hypotension in the rat. J Physiol. 1984 Sep;354:523–545. doi: 10.1113/jphysiol.1984.sp015391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bonventre J. V., Skorecki K. L., Kreisberg J. I., Cheung J. Y. Vasopressin increases cytosolic free calcium concentration in glomerular mesangial cells. Am J Physiol. 1986 Jul;251(1 Pt 2):F94–102. doi: 10.1152/ajprenal.1986.251.1.F94. [DOI] [PubMed] [Google Scholar]
  5. Brooks D. P., Koster P. F., Albrightson-Winslow C. R., Stassen F. L., Huffman W. F., Kinter L. B. SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatta). J Pharmacol Exp Ther. 1988 Apr;245(1):211–215. [PubMed] [Google Scholar]
  6. Clark B. J., Silva MR Jr E. An afferent pathway for the selective release of vasopressin in response to carotid occlusion and haemorrhage in the cat. J Physiol. 1967 Aug;191(3):529–542. doi: 10.1113/jphysiol.1967.sp008266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. DICKER S. E. A method for the assay of very small amounts of antidiuretic activity with a note on the antidiuretic titre of rat's blood. J Physiol. 1953 Oct;122(1):149–157. doi: 10.1113/jphysiol.1953.sp004986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gerstberger R., Fahrenholz F. Autoradiographic localization of V1 vasopressin binding sites in rat brain and kidney. Eur J Pharmacol. 1989 Aug 11;167(1):105–116. doi: 10.1016/0014-2999(89)90752-8. [DOI] [PubMed] [Google Scholar]
  9. Kinter L. B., Huffman W. F., Stassen F. L. Antagonists of the antidiuretic activity of vasopressin. Am J Physiol. 1988 Feb;254(2 Pt 2):F165–F177. doi: 10.1152/ajprenal.1988.254.2.F165. [DOI] [PubMed] [Google Scholar]
  10. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  11. László F. A., László F., Jr, De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev. 1991 Mar;43(1):73–108. [PubMed] [Google Scholar]
  12. Mah S. C., Hofbauer K. G. Evaluation of the pharmacologic properties of a vasopressin antagonist in Brattleboro rats. J Pharmacol Exp Ther. 1988 Jun;245(3):1028–1032. [PubMed] [Google Scholar]
  13. Manning M., Sawyer W. H. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med. 1989 Dec;114(6):617–632. [PubMed] [Google Scholar]
  14. Michell R. H., Kirk C. J., Billah M. M. Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans. 1979 Oct;7(5):861–865. doi: 10.1042/bst0070861. [DOI] [PubMed] [Google Scholar]
  15. Nakahara T., Terada S., Pincus J., Flouret G., Hechter O. Neurohypophyseal hormone-responsive renal adenylate cyclase. I. General characteristics of the neurohypophyseal hormone-sensitive adenylate cyclase in bovine renal medullary membranes prepared using a double phase polymer system. J Biol Chem. 1978 May 10;253(9):3211–3218. [PubMed] [Google Scholar]
  16. Nakamura T., Tomomura A., Noda C., Shimoji M., Ichihara A. Acquisition of a beta-adrenergic response by adult rat hepatocytes during primary culture. J Biol Chem. 1983 Aug 10;258(15):9283–9289. [PubMed] [Google Scholar]
  17. Yamamura Y., Ogawa H., Chihara T., Kondo K., Onogawa T., Nakamura S., Mori T., Tominaga M., Yabuuchi Y. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991 Apr 26;252(5005):572–574. doi: 10.1126/science.1850553. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES